Development of the Enabling Route for a Novel HCV NS3/4A Inhibitor, Furaprevir-Reference-Cited by-同舟云学术

Development of the Enabling Route for a Novel HCV NS3/4A Inhibitor, Furaprevir

Published:2022-02-18 Issue:4 Volume:26 Page:1078-1093
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Zhang Weihong¹^ORCID,Li Shixi²,Liu Haiwang²^ORCID,Zhang Yingjun²³,Xie Hongpeng²,Peng Dahua²,Peng Hongtao²,Ou Zijian²,Peng Zhihong¹,Dong Wanrong¹^ORCID,An Delie¹

Affiliation:

1. State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China

2. The State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co. Ltd., Dongguan 523871, P. R. China

3. Dongguan HEC TaiGen Biopharmaceuticals Co. Ltd., Dongguan 523000, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.1c00315

Reference25 articles.

1. World Health Organization. Hepatitis-C. https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c (accessed July 27, 2021).

2. About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus

3. Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection

4. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir

5. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applications of palladium-catalyzed C–N cross-coupling reactions in pharmaceutical compounds;RSC Advances;2023

2. Synthesis of Furaprevir;Synfacts;2022-07-18

3. Furaprevir. HCV NS3/4A protease inhibitor, Treatment of chronic hepatitis C virus infection tract infection;Drugs of the Future;2022